Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
Jeffrey Crowley, Diamant Thaçi, P. Joly, et al.
Journal of the American Academy of Dermatology (2017) Vol. 77, Iss. 2, pp. 310-317.e1
Open Access | Times Cited: 168

Showing 1-25 of 168 citing articles:

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Farzad Alinaghi, Monika Calov, Lars Erik Kristensen, et al.
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 251-265.e19
Open Access | Times Cited: 503
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets, Craig L. Leonardi, Dawn Marie R. Davis, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1073-1113
Closed Access | Times Cited: 379
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2021) Vol. 35, Iss. 2, pp. 281-317
Open Access | Times Cited: 146
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
Bruce Strober, Andrew Blauvelt, Richard B. Warren, et al.
Journal of the European Academy of Dermatology and Venereology (2024) Vol. 38, Iss. 8, pp. 1543-1554
Open Access | Times Cited: 21
Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment
Stephen Chu‐Sung Hu, Cheng‐Che E. Lan
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 10, pp. 2211-2211
Open Access | Times Cited: 168
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Eric L. Simpson, Shinichi Imafuku, Yves Poulin, et al.
Journal of Investigative Dermatology (2018) Vol. 139, Iss. 5, pp. 1063-1072
Open Access | Times Cited: 103
Systemic rheumatic diseases: From biological agents to small molecules
Piercarlo Sarzi‐Puttini, Angela Ceribelli, Daniela Marotto, et al.
Autoimmunity Reviews (2019) Vol. 18, Iss. 6, pp. 583-592
Open Access | Times Cited: 77
Long-term Safety of Oral Systemic Therapies for Psoriasis: A Comprehensive Review of the Literature
Deepak Balak, Sascha Gerdes, Aurora Parodi, et al.
Dermatology and Therapy (2020) Vol. 10, Iss. 4, pp. 589-613
Open Access | Times Cited: 77
Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
Silvio Danese, Markus F. Neurath, Adam Kopoń, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 18, Iss. 11, pp. 2526-2534.e9
Open Access | Times Cited: 72
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
Paolo Gisondi, Maria Concetta Fargnoli, Paolo Amerio, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157
Open Access | Times Cited: 63
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Martin Kolb, Bruno Crestani, Toby M. Maher
European Respiratory Review (2023) Vol. 32, Iss. 167, pp. 220206-220206
Open Access | Times Cited: 39
Alopecia Areata: Current Treatments and New Directions
Dante Dahabreh, Seungyeon Jung, Yael Renert‐Yuval, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 895-912
Closed Access | Times Cited: 37
Management of Psoriasis Patients with Serious Infectious Diseases
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2099-2111
Open Access | Times Cited: 9
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
Tiago Torres, L. Puig
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 1, pp. 23-32
Closed Access | Times Cited: 81
Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data
Imke Redeker, Falk Hoffmann, Johanna Callhoff, et al.
Annals of the Rheumatic Diseases (2018) Vol. 77, Iss. 7, pp. 1017-1024
Open Access | Times Cited: 68
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation
Emily Baumrin, Abby Van Voorhees, Amit Garg, et al.
Journal of the American Academy of Dermatology (2019) Vol. 81, Iss. 1, pp. 102-110
Closed Access | Times Cited: 68
Apremilast in psoriasis and beyond: Big hopes on a small molecule
Sunil Dogra, T. P. Afra, TMuhammed Razmi
Indian Dermatology Online Journal (2019) Vol. 10, Iss. 1, pp. 1-1
Open Access | Times Cited: 57
Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)
Richard H. Woods
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 8, pp. 2386-2395
Closed Access | Times Cited: 32
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
Philip J. Mease, Gülen Hatemi, Maria Paris, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 5, pp. 809-820
Open Access | Times Cited: 18
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during theCOVID‐19 pandemic
Jose W. Ricardo, Shari R. Lipner
Dermatologic Therapy (2020) Vol. 33, Iss. 5
Open Access | Times Cited: 48
Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study
Amy S. Paller, Ying Hong, Emily M. Becker, et al.
Journal of the American Academy of Dermatology (2019) Vol. 82, Iss. 2, pp. 389-397
Open Access | Times Cited: 44
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
Gerasimos Evangelatos, Vasiliki Koulouri, Alexios Iliopoulos, et al.
Therapeutic Advances in Musculoskeletal Disease (2020) Vol. 12
Open Access | Times Cited: 41
German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations
Alexander Nast, Andreas Altenburg, Matthias Augustin, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2021) Vol. 19, Iss. 7, pp. 1092-1115
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top